Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.
extranodal marginal zone lymphoma
frontline treatment
rituximab
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
revised:
05
09
2024
received:
09
07
2024
accepted:
07
09
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
19
9
2024
Statut:
aheadofprint
Résumé
First-line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional treatment and systemic chemo-immunotherapy, can be used depending on the site and stage of disease. Single-agent rituximab is a useful approach in the setting of localized, low-intermediate risk EMZL. The aim our research was to analyze the effectiveness and safety of single-agent rituximab (375 mg/m
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : RC-2024-2790109
Informations de copyright
© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.
Références
P. L. Zinzani and A. Broccoli, “Marginal Zone B‐Cell Lymphomas,” in Williams Hematology (New York, NY: McGraw‐Hill, 2016), 1663–1669.
J. R. Cerhan and T. M. Habermann, “Epidemiology of Marginal Zone Lymphoma,” Annals of Lymphoma 5 (2021): 1.
A. Smith, S. Crouch, S. Lax, et al., “Lymphoma Incidence, Survival and Prevalence 2004‐2014: Sub‐Type Analyses From the UK's Haematological Malignancy Research Network,” British Journal of Cancer 112, no. 9 (2015): 1575–1584.
E. Chanudet, Y. Zhou, C. M. Bacon, et al., “Chlamydia Psittaci Is Variably Associated With Ocular Adnexal MALT Lymphoma in Different Geographical Regions,” Journal of Pathology 209, no. 3 (2006): 344–351.
L. Cerroni, N. Zöchling, B. Pütz, and H. Kerl, “Infection by Borrelia Burgdorferi and Cutaneous B‐Cell Lymphoma,” Journal of Cutaneous Pathology 24, no. 8 (1997): 457–461.
K. E. Smedby, H. Hjalgrim, J. Askling, et al., “Autoimmune and Chronic Inflammatory Disorders and Risk of Non‐Hodgkin Lymphoma by Subtype,” Journal of the National Cancer Institute 98, no. 1 (2006): 51–60.
E. Zucca and F. Bertoni, “The Spectrum of MALT Lymphoma at Different Sites: Biological and Therapeutic Relevance,” Blood 127, no. 17 (2016): 2082–2092.
A. Zullo, C. Hassan, F. Cristofari, et al., “Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa‐Associated Lymphoid Tissue Lymphoma,” Clinical Gastroenterology and Hepatology 8, no. 2 (2010): 105–110.
E. Zucca, C. Copie‐Bergman, U. Ricardi, C. Thieblemont, M. Raderer, and M. Ladetto, “Gastric Marginal Zone Lymphoma of MALT Type: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up,” Annals of Oncology 24, no. Suppl 6 (2013): vi144–vi148.
A. Stathis, C. Chini, F. Bertoni, et al., “Long‐Term Outcome Following Helicobacter pylori Eradication in a Retrospective Study of 105 Patients With Localized Gastric Marginal Zone B‐Cell Lymphoma of MALT Type,” Annals of Oncology 20, no. 6 (2009): 1086–1093.
P. Fang, J. R. Gunther, C. C. Pinnix, et al., “A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa‐Associated Lymphoid Tissue (MALT) Lymphoma,” International Journal of Radiation Oncology, Biology, Physics 109, no. 5 (2021): 1414–1420.
K. Isobe, Y. Kagami, K. Higuchi, et al., “A Multicenter Phase II Study of Local Radiation Therapy for Stage IEA Mucosa‐Associated Lymphoid Tissue Lymphomas: A Preliminary Report From the Japan Radiation Oncology Group (JAROG),” International Journal of Radiation Oncology, Biology, Physics 69, no. 4 (2007): 1181–1186.
J. S. Goda, M. Gospodarowicz, M. Pintilie, et al., “Long‐Term Outcome in Localized Extranodal Mucosa‐Associated Lymphoid Tissue Lymphomas Treated With Radiotherapy,” Cancer 116, no. 16 (2010): 3815–3824.
A. Ruskoné‐Fourmestraux, T. Matysiak‐Budnik, B. Fabiani, et al., “Exclusive Moderate‐Dose Radiotherapy in Gastric Marginal Zone B‐Cell MALT Lymphoma: Results of a Prospective Study With a Long Term Follow‐Up,” Radiotherapy and Oncology 117, no. 1 (2015): 178–182.
C. C. Pinnix, J. R. Gunther, S. A. Milgrom, et al., “Outcomes After Reduced‐Dose Intensity Modulated Radiation Therapy for Gastric Mucosa‐Associated Lymphoid Tissue (MALT) Lymphoma,” International Journal of Radiation Oncology, Biology, Physics 104, no. 2 (2019): 447–455.
M. Dreyling, C. Thieblemont, A. Gallamini, et al., “ESMO Consensus Conferences: Guidelines on Malignant Lymphoma. Part 2: Marginal Zone Lymphoma, Mantle Cell Lymphoma, Peripheral T‐Cell Lymphoma,” Annals of Oncology 24, no. 4 (2013): 857–877.
A. Conconi, G. Martinelli, C. Thiéblemont, et al., “Clinical Activity of Rituximab in Extranodal Marginal Zone B‐Cell Lymphoma of MALT Type,” Blood 102, no. 8 (2003): 2741–2745.
I. S. Lossos, D. Morgensztern, M. Blaya, A. Alencar, D. Pereira, and J. Rosenblatt, “Rituximab for Treatment of Chemoimmunotherapy Naive Marginal Zone Lymphoma,” Leukemia & Lymphoma 48, no. 8 (2007): 1630–1632.
E. Zucca, A. Conconi, G. Martinelli, et al., “Final Results of the IELSG‐19 Randomized Trial of Mucosa‐Associated Lymphoid Tissue Lymphoma: Improved Event‐Free and Progression‐Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy,” Journal of Clinical Oncology 35, no. 17 (2017): 1905–1912.
A. Salar, E. Domingo‐Domenech, C. Panizo, et al., “First‐Line Response‐Adapted Treatment With the Combination of Bendamustine and Rituximab in Patients With Mucosa‐Associated Lymphoid Tissue Lymphoma (MALT2008‐01): A Multicentre, Single‐Arm, Phase 2 Trial,” Lancet Haematology 1, no. 3 (2014): e104–e111.
A. Salar, E. Domingo‐Domenech, C. Panizo, et al., “Long‐Term Results of a Phase 2 Study of Rituximab and Bendamustine for Mucosa‐Associated Lymphoid Tissue Lymphoma,” Blood 130, no. 15 (2017): 1772–1774.
M. Raderer, G. Jäger, S. Brugger, et al., “Rituximab for Treatment of Advanced Extranodal Marginal Zone B Cell Lymphoma of the Mucosa‐Associated Lymphoid Tissue Lymphoma,” Oncology 65, no. 4 (2003): 306–310.
G. Martinelli, D. Laszlo, A. J. Ferreri, et al., “Clinical Activity of Rituximab in Gastric Marginal Zone Non‐Hodgkin's Lymphoma Resistant to or Not Eligible for Anti‐Helicobacter pylori Therapy,” Journal of Clinical Oncology 23, no. 9 (2005): 1979–1983.
M. E. Williams, F. Hong, R. D. Gascoyne, et al., “Rituximab Extended Schedule or Retreatment Trial for Low Tumour Burden Non‐follicular Indolent B‐Cell Non‐Hodgkin Lymphomas: Eastern Cooperative Oncology Group Protocol E4402,” British Journal of Haematology 173, no. 6 (2016): 867–875.
B. D. Cheson, R. I. Fisher, S. F. Barrington, et al., “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non‐Hodgkin Lymphoma: The Lugano Classification,” Journal of Clinical Oncology 32, no. 27 (2014): 3059–3067.
B. D. Cheson, B. Pfistner, M. E. Juweid, et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology 25, no. 5 (2007): 579–586.
C. Thieblemont, L. Cascione, A. Conconi, et al., “A MALT Lymphoma Prognostic Index,” Blood 130, no. 12 (2017): 1409–1417.
J. P. Alderuccio, I. M. Reis, T. M. Habermann, et al., “Revised MALT‐IPI: A New Predictive Model That Identifies High‐Risk Patients With Extranodal Marginal Zone Lymphoma,” American Journal of Hematology 97, no. 12 (2022): 1529–1537.
L. Sena Teixeira Mendes, A. D Attygalle, and A. C Wotherspoon, “Helicobacter pylori Infection in Gastric Extranodal Marginal Zone Lymphoma of Mucosa‐Associated Lymphoid Tissue (MALT) Lymphoma: A Re‐Evaluation,” Gut 63, no. 9 (2014): 1526–1527.
L. M. Asenjo and J. P. Gisbert, “Prevalencia de la infección por Helicobacter pylori en el linfoma MALT gástrico: una revisión sistemática (Prevalence of Helicobacter pylori Infection in Gastric MALT Lymphoma: A Systematic Review),” Revista Española de Enfermedades Digestivas 99, no. 7 (2007): 398–404.
M. Keikha, A. Sahebkar, Y. Yamaoka, and M. Karbalaei, “Helicobacter pylori cagA Status and Gastric Mucosa‐Associated Lymphoid Tissue Lymphoma: A Systematic Review and Meta‐Analysis,” Journal of Health, Population, and Nutrition 41, no. 1 (2022): 2.
S. Luminari, M. Cesaretti, L. Marcheselli, et al., “Decreasing Incidence of Gastric MALT Lymphomas in the Era of Anti‐Helicobacter pylori Interventions: Results From a Population‐Based Study on Extranodal Marginal Zone Lymphomas,” Annals of Oncology 21, no. 4 (2010): 855–859.